Too much ara-C? Not enough daunorubicin?

It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).

Saved in:
Bibliographic Details
Published in:Blood 2011-02, Vol.117 (8), p.2299-2300
Main Author: Feldman, Eric J.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2011-01-328633